semaglutide 12.5 units Tirzepatide and key differences, weight loss results (2026) Semaglutide Dosing Guide (2026): Doses,

Quick Answer: Semaglutide is not established to directly cause joint pain based on FDA clinical trial data, though some patients report musculoskeletal discomfort that may result from indirect factors such as rapid weight loss or biomechanical changes

Tirzepatide followed as a dual receptor agonist, demonstrating superior weight reduction outcomes compared to semaglutide in head-to-head trials

Improved cardiovascular outcomes: As a GLP-1 agonist, Ozempic has been associated with decreased cardiovascular risk factors

Tirzepatide's dual-action mechanism has shown greater average weight loss in clinical trials, but semaglutide has a longer track record and remains highly effective for many patients